The research progress on de-escalation and optimization strategies for the treatment of early-stage breast cancer
10.3760/cma.j.cn112139-20241012-00459
- VernacularTitle:早期乳腺癌降阶梯优化治疗策略的研究进展
- Author:
Xiaopeng HAO
1
;
Song WU
;
Zefei JIANG
Author Information
1. 解放军总医院第一医学中心普通外科医学部，北京100853
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Antineoplastic protocols;
Targeted therapy;
Immunotherapy;
Surgical procedures, operative;
De-escalation therapy
- From:
Chinese Journal of Surgery
2025;63(8):682-689
- CountryChina
- Language:Chinese
-
Abstract:
With the advancement of precision medicine, the treatment of early-stage breast cancer is gradually moving toward standardized individualization. While ensuring therapeutic efficacy, increasing attention is being given to patients′ quality of life. In recent years, as clinical research data on targeted therapies for HER2-positive breast cancer, CDK4/6 inhibitors for hormone receptor-positive breast cancer, and immune checkpoint inhibitors for triple-negative breast cancer have accumulated, the treatment of early-stage breast cancer has become more precise and personalized. Furthermore, the growing body of clinical research on breast-conserving surgery, axillary preservation, and even the omission of primary tumor resection has significantly improved patients′ quality of life. These more effective drugs and advanced technologies provide the foundation for de-escalation treatment strategies in early-stage breast cancer, driving the development of a more refined, patient-centered treatment approach.
